Researchers find genes that fuse in cancer



With the festive season in full swing in Australia and elsewhere, in the run up to Christmas, scientists in the United States have made an attempt to ascertain if there is indeed a proven cure for a hangover. Hangover cures abound and range from the ludicrous and ridiculous to the seemingly sensible but according to

Full Post: Be warned - there’s no such thing as a hangover cure!

Using new technologies that make it easier to sequence the human genome, researchers at the University of Michigan Comprehensive Cancer Center have identified a series of genes that become fused when their chromosomes trade places with each other.

These recurrent gene fusions are thought to be the driving mechanism that causes certain cancers to develop.

The gene fusions discovered could potentially serve as a marker one day for diagnosing cancer or as a target for future drug development.

In the new study, published in Nature, the researchers identified several gene fusions in prostate cancer cells. Some of the fusions were seen in multiple cell lines studied, while other gene fusions appeared only once. The fusions were found only in cancer cells, and not in normal cells.

“We defined a new class of mutations in prostate cancer. The recurrent fusions are thought to be the driving mechanism of cancer. But we found other fusions as well, some of which were unique to individual patients. Our next step is to understand if these play a role in driving disease,” says Arul Chinnaiyan, M.D., Ph.D., director of the Michigan Center for Translational Pathology and S.P. Hicks Endowed Professor of Pathology at the U-M Medical School.

Chinnaiyan’s team was the first to identify rearrangements in chromosomes and fused genes in prostate cancer. Gene fusions had previously been known to play a role in blood cell cancers such as leukemia and lymphoma, and in Ewing’s sarcoma.

In the current study, the researchers showed that newer techniques could identify these gene fusions more quickly and easily.

The researchers used a technique called gene sequencing, which involves creating a library of all RNAs in a cell. Sequencing machines then run 24 hours a day for days at a time, reading the RNA. Once the sequencing is finished, researchers study the data searching for the gene fusions.

This is a more direct approach than the method Chinnaiyan’s lab used to first identify gene fusions in prostate cancer, a process called microarray. Using microarray technology, researchers had to first know where they wanted to look. With gene sequencing, the researchers can find what’s there without knowing where to look first.

“We now have the ability to use next generation sequencing technology. This will open up the field in cancer research,” says Chinnaiyan, a Howard Hughes Medical Institute investigator. While the current study focused on prostate cancer, his team is also looking at gene fusions involved in breast cancer, lung cancer and melanoma.

The findings: Researchers tested gene sequencing technology to see if they could re-discover the same gene fusions previously found using other technologies. In addition to verifying the known gene fusions, researchers found new gene fusions that were common among some tumor samples. Additional gene fusions were identified in individual tumor samples.

Additional authors: Christopher Maher, Ph.D., research fellow; Chandan Kumar-Sinha, Ph.D., research assistant professor of pathology; Xuhong Cao, research specialist; Shanker Kalyana-Sundaram, data architect; Bo Han, research fellow; Xiaojun Jing, Lee Sam, Terrence Barrette, systems analyst; and Nallasivam Palanisamy, Ph.D., research assistant professor of pathology

Funding: National Institutes of Health, Department of Defense and Early Detection Research Network

http://www.med.umich.edu/

Link




Cincinnati scientists have identified a new biomarker that could help predict a person’s risk of developing colon cancer and how aggressive it may become. The University of Cincinnati (UC) team has identified “hotspots”-areas of deleted genetic data-that play a critical role in regulating gene expression and influence colon cancer progression. Researchers speculate that these hotspots

Full Post: Potential new biomarker for colon cancer



Researchers at the University of Southern California (USC) have found that inactivating a specific biomarker for aggressive prostate cancer blocks the development of prostate cancer in animal models. Researchers say the upcoming study in the Proceedings of the National Academy of Sciences - now available online - may lead to a novel cancer therapy

Full Post: Discovery of novel approach to suppress prostate cancer progression



The report, entitled Cytosolic Phospholipase A2-: A Potential Therapeutic Target for Prostate Cancer, describes the possible role of an enzyme called cPLA2- in prostate cancer and its potential to be a treatment target for prostate cancers that no longer respond to hormone-related therapy. Hormone-related therapy is the first line of treatment for more advanced prostate

Full Post: Theraputic target for prostate cancer



A newly published genome sequence of a breast cancer cell line reveals a heavily rearranged genetic blueprint involving breaks and fusions of genes and a broken DNA repair machinery, said researchers at Baylor College of Medicine in a report that appears online in the journal Genome Research. “It’s like a computer program that has become

Full Post: Breast cancer genome shows instability of cancer



Prostate cancer - and perhaps other cancers - promotes the growth of new nerves and the branching axons that carry their messages, a finding associated with more aggressive tumors, said researchers from Baylor College of Medicine in the first report of the phenomenon that appears today in the journal Clinical Cancer Research. Previous research showed that prostate

Full Post: Prostate cancer tumors promote nerve growth